Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · China

Advanced Solid Tumors Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Shanghai 61 Beijing 56 Guangzhou 51 Hangzhou 28 Fuzhou 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.9 Suzhou Suncadia Biopharmaceuticals Co., Ltd.7 Jiangsu HengRui Medicine Co., Ltd.7 Shanghai Hengrui Pharmaceutical Co., Ltd.6 MediLink Therapeutics (Suzhou) Co., Ltd.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.5 Akeso4 Hansoh BioMedical R&D Company4 Bio-Thera Solutions3 Beijing Geekgene Technology Co., LTD3 Bayer3 Qilu Pharmaceutical Co., Ltd.3 Multitude Therapeutics Inc.3 Changchun GeneScience Pharmaceutical Co., Ltd.3 Lepu Biopharma Co., Ltd.2 Merck Sharp & Dohme LLC2 Sheng Zhang2 Hangzhou Converd Co., Ltd.2 CStone Pharmaceuticals2 TCRx Therapeutics Co.Ltd2 NING LI2 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company2 CSPC Megalith Biopharmaceutical Co.,Ltd.2 VelaVigo Bio Inc2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 Hangzhou DAC Biotechnology Co., Ltd.2 HighField Biopharmaceuticals Corporation2 CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2 Evopoint Biosciences Inc.2 Shanghai Pharmaceuticals Holding Co., Ltd2 AbbVie2 Haisco Pharmaceutical Group Co., Ltd.2 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.2 Keymed Biosciences Co.Ltd2 Jiangsu Hansoh Pharmaceutical Co., Ltd.2 Ensem Therapeutics1 Risen (Suzhou) Pharma Tech Co., Ltd.1 The Affiliated Hospital of Xuzhou Medical University1 Danatlas Pharmaceuticals Co., Ltd1 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.1 Beijing Biotech1 Anhui Provincial Hospital1 Zhejiang Provincial People's Hospital1 Joint Biosciences Ltd.1 Foresight Therapeutics (Hefei) Co., Ltd.1 CD (Suzhou) Biopharma Co., Ltd.1 Shanghai AB PharmaTech Ltd.1 AskGene Pharma, Inc.1 Zhuhai Fapon Biopharma Co., Ltd.1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.1 Peking University Shenzhen Hospital1 BeOne Medicines1 Henan Genuine Biotech Co., Ltd.1 TCRCure Biopharma Ltd.1 Genfleet Therapeutics (Shanghai) Inc.1 Nanjing Zenshine Pharmaceuticals1 Shanghai NK Cell Technology Co., LTD1 Betta Pharmaceuticals Co., Ltd.1 Shanghai Junshi Bioscience Co., Ltd.1 Peking University1 Shaoxing Salvectors Biotechnology LTD.1 Shanghai Juncell Therapeutics1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 The First Hospital of Jilin University1 InxMed (Shanghai) Co., Ltd.1 Chongqing Peg-Bio Biopharm Co., Ltd.1 Novartis Pharmaceuticals1 Jemincare1 InSilico Medicine Hong Kong Limited1 Grit Biotechnology1 Shenyang Sunshine Pharmaceutical Co., LTD.1 Shanghai SciBrunch Therapeutics Co., Ltd.1 Nutshell Therapeutics (Shanghai) Co., LTD.1 Vividion Therapeutics, Inc.1 Beijing Kanghong Biopharmaceutical Co., Ltd.1 Wigen Biomedicine Technology (Shanghai) Co., Ltd.1 Mainline Biosciences (Shanghai) Co., Ltd1 Hangzhou Sumgen Biotech Co., Ltd.1 Chipscreen Biosciences, Ltd.1 Convalife (Shanghai) Co., Ltd.1 Ganzhou Hemay Pharmaceutical Co., Ltd1 Tianjin Medical University Cancer Institute and Hospital1 Abion Inc1 Nanjing Jingao biomidical technology Co. Ltd.1 The First Affiliated Hospital of Xiamen University1 Shanghai Pushi Medical Science Co. Ltd1 Shanghai Allink Biotherapeutics Co., Ltd.1 Xizang Haisco Pharmaceutical Co., Ltd1 WestVac Biopharma Co., Ltd.1 Corregene Biotechnology Co., Ltd1 Beijing InnoCare Pharma Tech Co., Ltd.1 Incyte Corporation1 Signet Therapeutics1 Sichuan Honghe Biotechnology Co., Ltd.1 Suzhou Forlong Biotechnology Co., Ltd1 Jiangsu Simcere Pharmaceutical Co., Ltd.1 Vibrant Sciences Limited1 Eikon Therapeutics1 Ascentawits Pharmaceuticals, Ltd1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1 Base Therapeutics (Shanghai) Co., Ltd.1 Dizal Pharmaceuticals1 DualityBio Inc.1 Zhejiang Hospital1 NextCure, Inc.1 Bristol-Myers Squibb1 Hangzhou Adcoris Biopharmacy Co., Ltd1 Beijing StarMab Biomed Technology Ltd1 Shandong Suncadia Medicine Co., Ltd.1 Xuanzhu Biopharmaceutical Co., Ltd.1 Chengdu JOYO pharma Co., Ltd.1 changjianhua1 West China Hospital1 Shanghai Institute Of Biological Products1
Site location
Shanghai61 Beijing56 Guangzhou51 Hangzhou28 Fuzhou25 Changsha20 Harbin17 Chengdu14 Zhengzhou14 Chongqing13 Wuhan13 Jinan13 Nanning11 Nanchang10 Hefei9 Shenyang9 Changchun8 Tianjin7 Shenzhen6 Nanjing5 Taiyuan5 Anyang4 Xuzhou4 Xiamen4 Xinxiang4 Shijiazhuang4 Shandong3 Baoding3 Zhejiang3 Wenzhou2 Meizhou2 Xi’an2 Luoyang2 Jilin City2 Haerbin2 Langfang2 Lanzhou2 Linyi2 Hebei2 Guiyang2 Chengde2 Dalian1 Chongqicun1 Nanyang1 Liaocheng1 Neijiang1 Jiamusi1 Chizhou1 Wuwei1 Haikou1 Xi'an1 Fuxin1 Yongzhou1 Guanzhou1 Dongguan1 Fujian1 Heilongjiang1 Guangdong1 Shantou1 Suzhou1 Tianjing1 Jining1 Bengbu1 Dongwan1 Shengyang1
All 65 locations
Target enrolment
to

Advanced Solid Tumors trials in China

187 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
154
Tianjin
2026-11-30
Not yet open
Keymed Biosciences Co.Ltd
Phase 1/2
128
Shanghai
2026-11-27
Not yet open
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Fuzhou, Jinan, Shanghai, Hangzhou
2026-10-18
Recruiting
Beijing StarMab Biomed Technology Ltd
Phase 1
72
Beijing
2026-10-09
Recruiting
Akeso
Phase 1
243
Harbin, Shanghai, Chengdu
2026-09-30
Not yet open
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
99
Shanghai
2026-09-10
Recruiting
HighField Biopharmaceuticals Corporation
Phase 1
45
Beijing, Guangzhou
2026-09-08
Recruiting
SKB565 for Injection in Advanced Solid Tumors
NCT07545265Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
180
Guangzhou
2026-08-31
Not yet open
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
30
Hebei
2026-08-01
Recruiting
VelaVigo Bio Inc
Phase 1/2
230
Beijing, Shanghai, Hangzhou
2026-07-30
Recruiting
CStone Pharmaceuticals
Phase 1
310
Shanghai
2026-07-16
Not yet open
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
NCT07624214Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase 1
198
Hangzhou
2026-07
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
NCT07699757Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
DrugsHSK41959·Cisplatin/Carboplatin·Sintilimab·Nab-paclitaxel
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
258
Shanghai
2026-07
Recruiting
Allogeneic WTX-212C in Advanced Solid Tumors
NCT07556653Advanced Solid Tumors
Zhejiang Provincial People's Hospital
Early Phase 1
24
Hangzhou
2026-06-26
Not yet open
Peking University Shenzhen Hospital
Early Phase 1
10
Shenzhen
2026-06-10
Not yet open
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
NCT07615894Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
WestVac Biopharma Co., Ltd.
Phase 1
9
Chengdu
2026-06-01
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
530
Shanghai
2026-06-01
Not yet open
Beijing Geekgene Technology Co., LTD
Early Phase 1
10
Beijing
2026-06
Not yet open
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Not yet open
FAK Inhibitor in Patients With Advanced Solid Tumors
NCT07596381Advanced Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1
75
Hangzhou
2026-05-30
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-05-10
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
Joint Biosciences Ltd.
Phase 1
18
Beijing
2026-04-21
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
63
Shanghai
2026-04-10
Recruiting
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
56
Guangzhou
2026-04-07
Not yet open
Beijing Geekgene Technology Co., LTD
Phase 1
15
Beijing
2026-04
Not yet open
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2026-04
Active, closed
Corregene Biotechnology Co., Ltd
Phase 1
6
Beijing
2026-03-26
Recruiting
Base Therapeutics (Shanghai) Co., Ltd.
Early Phase 1
18
Beijing
2026-03-09
Recruiting
SKB105 for Injection in Advanced Solid Tumors
NCT07380386Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
256
Beijing, Shanghai
2026-03-05
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
DrugFludarabine
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Beijing Geekgene Technology Co., LTD
Early Phase 1
10
Nanchang
2026-02-13
Not yet open
Evopoint Biosciences Inc.
Phase 1/2
150
Guangzhou
2026-01-31
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
120
Hangzhou
2026-01-29
Recruiting
Dizal Pharmaceuticals
Phase 1/2
203
Beijing
2026-01-29
Recruiting
Vibrant Sciences Limited
Phase 1/2
146
Guangzhou
2026-01-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2026-01-10
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Recruiting
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
130
Guangzhou
2026-01-08
Recruiting
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Nanjing Zenshine Pharmaceuticals
Phase 1
80
Shanghai
2025-12-26
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
TCRx Therapeutics Co.Ltd
Phase 1
30
Shanghai
2025-12-19
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
170
Shenyang
2025-12-10
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
24
Xinxiang
2025-12-03
Recruiting
TCRx Therapeutics Co.Ltd
Phase 1
30
Beijing
2025-12-01
Recruiting
FL-261 Imaging for Cancer Diagnosis and Staging
NCT07510321Non-Small Cell Lung Cancer, Colorectal Cancer, Head & Neck Cancer, Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
12
Wuhan
2025-11-27
Recruiting
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2
20
Beijing
2025-11-20
Recruiting
GenSci139 in Patients With Advanced Solid Tumors
NCT07230977Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
280
Jinan
2025-11-19
Recruiting
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
NCT07702162Advanced Solid Tumors, Cancer
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
49
Fuzhou, Shanghai
2025-11-14
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
444
Shanghai
2025-11-13
Recruiting
Hansoh BioMedical R&D Company
Phase 1
60
Guangzhou
2025-11-13
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Phase 1
12
Xuzhou
2025-11-12
Recruiting
Grit Biotechnology
Phase 1/2
78
Guangzhou, Nanning, Changsha, Shanghai, Chengdu
2025-11-01
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsTam-Peli·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
Jemincare
Phase 1
102
Beijing
2025-10-22
Not yet open
The First Hospital of Jilin University
Phase 1
30
Changchun
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2
104
Shanghai
2025-10-15
Recruiting
Hansoh BioMedical R&D Company
Phase 1
18
Changsha
2025-09-23
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
NCT07164950Urothelial Carcinoma, Advanced Solid Tumors, Chemotherapy-Induced Peripheral Neuropathy, Antibody-drug Conjugates
Sheng Zhang
Not applicable
58
Shanghai
2025-08-30
Recruiting
Anhui Provincial Hospital
Early Phase 1
36
Hefei
2025-08-29
Active, closed
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
266
Shenyang
2025-08-11
Recruiting
Akeso
Phase 1
200
Guangzhou
2025-08-07
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
129
Shanghai
2025-08-06
Recruiting
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Beijing, Guangzhou, Nanchang, Shanghai, Xi'an
2025-08-04
Not yet open
changjianhua
Phase 1
25
Shenzhen
2025-08-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
410
Guangzhou
2025-08
Not yet open
Danatlas Pharmaceuticals Co., Ltd
Phase 1
228
Beijing
2025-07-31
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
212
Shanghai
2025-07
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
434
Guangzhou
2025-06-27
Recruiting
Hangzhou Converd Co., Ltd.
Not applicable
24
Xiamen
2025-06-23
Recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2025-06-16
Recruiting
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Guangzhou, Wuhan, Nanchang, Taiyuan, Hangzhou
2025-06-12
Recruiting
HighField Biopharmaceuticals Corporation
Early Phase 1
10
Chengdu
2025-06-11
Recruiting
Shanghai Institute Of Biological Products
Phase 1
156
Fuzhou
2025-06-11
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
72
Shanghai
2025-05-29
Recruiting
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
76
Guangzhou
2025-05-28
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
DrugsAK129·Penpulimab·Cis-platinum·Cetuximab
Akeso
Phase 1/2
230
Shenyang
2025-05-21
Recruiting
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2
156
Jinan
2025-05-08
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 1
256
Hangzhou
2025-05
Recruiting
Eikon Therapeutics
Phase 1/2
130
Chongqing, Jinan, Shanghai
2025-04-30
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
Hansoh BioMedical R&D Company
Phase 1
1,050
Guangzhou
2025-04-15
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
245
Guiyang, Nanjing, Shanghai
2025-04-11
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
150
Jinan
2025-04-02
Not yet open
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
27
Harbin
2025-04
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
260
Shanghai
2025-03-28
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
400
Taiyuan
2025-03-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-03-18
Recruiting
First in Human Study of YB1-X7 Injection
NCT06889675Advanced Solid Tumors
DrugsTuoyi·Toripalimab
Shaoxing Salvectors Biotechnology LTD.
Not applicable
48
Langfang
2025-03-04
Not yet open
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
NCT06825455Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer
DrugsFludarabine·Cyclophosphamide
Peking University
Early Phase 1
18
Beijing
2025-03-01
Not yet open
NING LI
Phase 4
3,000
Langfang
2025-03-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
876
Guangzhou
2025-02-18
Recruiting
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
Shanghai NK Cell Technology Co., LTD
Phase 1
76
Beijing
2025-02-07
Recruiting
SKB445 for Injection in Solid Tumors
NCT06826040Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
126
Jinan
2025-02-05
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1
100
Beijing
2025-01-21
Recruiting
CD (Suzhou) Biopharma Co., Ltd.
Phase 1
137
Tianjin
2025-01-08
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Recruiting
Sheng Zhang
Phase 2
84
Shanghai
2025-01-01
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
48
Shanghai
2024-12-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
180
Jilin City
2024-12-13
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
142
Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi
2024-12-12
Recruiting
Signet Therapeutics
Phase 1
102
Beijing
2024-12-12
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
115
Chongqing
2024-12-10
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Shanghai, Chongqing
2024-12-06
Not yet open
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-12
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
162
Chengdu
2024-11-13
Active, closed
NING LI
Early Phase 1
18
Beijing
2024-11-08
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
290
Beijing
2024-11-05
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
350
Wuhan
2024-10-31
Recruiting
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
201
Shanghai
2024-10-04
Recruiting
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
528
Shanghai
2024-08-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT07923214Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Phase 1
30
Fuzhou, Dalian, Shanghai, Chengdu
2024-07-02
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
NCT06443489Advanced Solid Tumors
DrugSHR-4849
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
80
Jilin City
2024-06-26
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Early Phase 1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
80
Beijing
2024-05-27
Active, closed
Bio-Thera Solutions
Phase 1/2
218
Guangzhou
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Active, closed
Bio-Thera Solutions
Phase 1/2
112
Hangzhou
2024-04-12
Recruiting
Hansoh BioMedical R&D Company
Phase 1
1,048
Shanghai
2024-04-11
Recruiting
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Recruiting
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580Malignant Melanoma, Advanced Solid Tumors
DrugAMT-253
Multitude Therapeutics Inc.
Phase 1/2
96
Beijing
2024-01-31
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Recruiting
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2
306
Zhengzhou
2024-01-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
Chengdu JOYO pharma Co., Ltd.
Phase 1
75
Shanghai
2024-01-01
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
240
Guangzhou
2023-12-25
Not yet open
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an
2023-10-17
Active, closed
Akeso
Phase 1/2
216
Harbin
2023-10-16
Recruiting
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Active, closed
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
TCRCure Biopharma Ltd.
Phase 1
18
Chongqing
2023-06-01
Active, closed
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
63
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Recruiting
Abion Inc
Phase 2
178
2023-01-17
Recruiting
Phase 1 Trial of KH617
NCT05667194Advanced Solid Tumors
Sichuan Honghe Biotechnology Co., Ltd.
Phase 1
45
Beijing
2022-12-26
Active, closed
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Recruiting
Bio-Thera Solutions
Phase 1
182
Chongqing, Hangzhou
2022-11-30
Active, closed
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Active, closed
Bayer
Phase 1
129
Guangzhou, Changchun, Linyi
2022-10-11
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
18
Guangzhou, Changsha
2022-06-30
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
246
Tianjin
2022-03-16
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an
2022-01-04
Recruiting
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
NCT07793214Advanced Solid Tumors, Advanced Solid Tumors Cancer
Zhejiang Hospital
Observational
500
Hangzhou
2022-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Recruiting
Shanghai Juncell Therapeutics
Early Phase 1
20
Shanghai
2021-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Guangzhou
2019-10-30
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
AbbVie
Phase 1
150
2019-05-21
Rows per page Showing 1–187 of 187
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 187 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in China?

135 of the 187 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 34 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 187 studies
PhaseStudiesRecruitingShare
Phase 1997052.9%
Phase 1/2614732.6%
Early Phase 11286.4%
Phase 2854.3%
Not applicable432.1%
Observational221.1%
Phase 4100.5%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.99
Jiangsu HengRui Medicine Co., Ltd.75
Suzhou Suncadia Biopharmaceuticals Co., Ltd.76
Shanghai Hengrui Pharmaceutical Co., Ltd.65
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.55
MediLink Therapeutics (Suzhou) Co., Ltd.54
Akeso43
Hansoh BioMedical R&D Company44
Bayer31
Beijing Geekgene Technology Co., LTD31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.